Multiple Origins of Drug Resistance Mutation in HIV Patients
Author Information
Author(s): Amit Kapoor, Beth Shapiro, Robert W. Shafer, Nancy Shulman, Soo-Yon Rhee, Eric L. Delwart
Primary Institution: Blood Systems Research Institute, San Francisco, CA, USA
Hypothesis
Is the L90M protease inhibitor resistance mutation selected only once or multiple times in HIV patients undergoing salvage therapy?
Conclusion
The study found that early L90M mutants can be replaced by independently selected L90M mutations rather than by descendants of earlier mutants.
Supporting Evidence
- The L90M mutation was found to have multiple origins in at least 5 out of 15 patients.
- The study used Bayesian evolutionary analysis to determine the origins of L90M mutations.
- Early L90M variants were often replaced by independently selected L90M mutations.
Takeaway
Some HIV patients can develop the same drug resistance mutation in different ways, meaning the virus can change a lot even when treated.
Methodology
The study used L90M allele specific PCR to analyze viral genome regions in patients and compared early and later L90M variants.
Potential Biases
Potential biases may arise from the selection of patients and the methods used for sequencing.
Limitations
The study's conclusions are based on a limited number of patients and may not be generalizable.
Participant Demographics
Patients undergoing salvage therapy for HIV with detectable L90M mutations.
Statistical Information
P-Value
p ≤ 0.05
Statistical Significance
p ≤ 0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website